

CLAIM AMENDMENTS

1-27. (canceled)

28. (previously presented): A method to identify an antagonist of a T-type calcium channel which method comprises:

- a) contacting a recombinant cell expressing the α_1 subunit of a heterologous T-type calcium channel with a known agonist of said T-type calcium channel;
- b) contacting said cell with a compound to be tested; and
- c) determining the ability of said compound to diminish the activation of said α_1 subunit by said agonist;

wherein said α_1 subunit is functional as a T-type calcium ion channel and is encoded by a nucleotide sequence which hybridizes under conditions of stringency corresponding to washing at 62° C in 0.2 x SSPE/0.1% SDS to a nucleic acid comprising SEQ ID NO: 23 and

wherein said activating comprises enhancing the flow of calcium ions into said cell in the presence as compared to the absence of said agonist;

whereby a compound which diminishes the activation of said α_1 subunit by said agonist is identified as an antagonist.

29. (previously presented): The method of claim 28 wherein said activation is measured by measuring the current through the calcium channel before and after said contacting of said cell with said compound.

30. (previously presented): The method of claim 28, wherein said cells contain a fluorescent dye sensitive to intracellular calcium concentration and said activation is determined by observing a change in the fluorescence of said dye when said contacting is performed.

31. (previously presented): A method to prescreen compounds as agonists or antagonists of T-type calcium ion channels by virtue of their ability to bind said T-type channels which method comprises:

- a) contacting a recombinant cell expressing the α_1 subunit of a heterologous T-type calcium channel with a compound to be tested; and
- b) determining the ability of said compound to bind to said cell expressing said α_1 subunit;

wherein said binding is determined by observing competitive binding with a known agonist or antagonist of said channel;

wherein said α_1 subunit is functional as a T-type calcium ion channel and is encoded by a nucleotide sequence which hybridizes under conditions of stringency corresponding to washing at 62°C in 0.2 x SSPE/0.1% SDS to a nucleic acid comprising SEQ ID NO: 23,

whereby a compound which is determined to bind said cell is identified as a compound which will behave as either an agonist or antagonist of a T-type calcium channel.

32-36. (canceled)

37. (previously presented): The method defined in claim 28 wherein the nucleic acid comprises SEQ ID NO: 23.

38-39. (canceled)

40. (previously presented): The method defined in claim 31 wherein the nucleic acid comprises SEQ ID NO: 23.

41-42. (canceled)

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. 381092000720.

Dated: January 26, 2006

Respectfully submitted,



By MICHAEL G. SMITH, Reg. No. 44,422

FOR

Kate H. Murashige

Registration No.: 29,959

MORRISON & FOERSTER LLP

12531 High Bluff Drive

Suite 100

San Diego, California 92130-2040

(858) 720-5112